Education
About Us
Working with TipRanks
Follow Us
ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Top Page
ABVC BioPharma, Inc.
(NASDAQ:ABVC)
33Underperform
ABVC BioPharma, Inc. (ABVC) vs. S&P 500 (SPY)
Market Cap
$17.13M
Dividend YieldN/A
Average Volume (3M)360.15K
Price to Earnings (P/E)―
Beta (1Y)-0.63
Revenue Growth-31.04%
EPS Growth74.62%
CountryUS
Employees16
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.90
Shares Outstanding12,975,492
10 Day Avg. Volume359,225
30 Day Avg. Volume360,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.56
Price to Cash Flow (P/CF)13.00
P/FCF Ratio4.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ABVC BioPharma, Inc. Business Overview & Revenue Model
Company DescriptionABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
How the Company Makes MoneyABVC BioPharma, Inc. makes money primarily through the development and commercialization of its proprietary drug candidates. The company engages in licensing agreements and partnerships with other pharmaceutical companies to co-develop and co-promote its products, which can provide upfront payments, milestone payments, and royalties based on product sales. Additionally, ABVC may receive funding from governmental or non-governmental grants to support its research activities. As its drug candidates progress through clinical trials and receive regulatory approval, the company can generate revenue from the sales of these approved products.
ABVC BioPharma, Inc. Financial Statement Overview
Summary
ABVC BioPharma is struggling financially with consistent losses and negative cash flows. While there are slight improvements, high debt and poor profitability pose major challenges.Income Statement
ABVC BioPharma shows consistent negative net income and EBIT margins, indicating ongoing profitability challenges. Revenue growth showed volatility with a significant decline in 2023, recovering slightly in the TTM period. Gross profit margin improved in TTM but remains insufficient to offset high operating losses.20
Very Negative
Balance Sheet
The company's debt-to-equity ratio has improved but remains concerning due to high total debt levels. Equity ratio shows moderate stability, though stockholders' equity has fluctuated. The return on equity is negative due to persistent net losses.35
Negative
Cash Flow
ABVC BioPharma's cash flow metrics reveal negative free cash flow growth and operating cash flow, indicating liquidity challenges. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income to cash flow.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 509.79K | 152.43K | 969.78K | 355.80K | 483.05K | 701.72K | Gross Profit |
| 360.95K | -149.61K | 683.37K | 350.71K | 464.33K | 681.58K | EBIT |
| -6.33M | -8.22M | -15.11M | -11.35M | -8.51M | -3.46M | EBITDA |
| -6.36M | -8.13M | -15.20M | -10.97M | -10.37M | -3.47M | Net Income Common Stockholders |
| -8.24M | -10.52M | -16.31M | -12.04M | -10.59M | -3.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 0.00 | 139.47K | 161.06K | 5.94M | 4.27M | 144.29K | Total Assets |
| 275.71K | 14.49M | 9.86M | 13.70M | 11.61M | 6.93M | Total Debt |
| 848.35K | 2.28M | 3.05M | 3.11M | 6.48M | 4.58M | Net Debt |
| 848.35K | 2.22M | 2.97M | -2.72M | 2.21M | 4.44M | Total Liabilities |
| 2.84M | 6.36M | 6.24M | 4.83M | 8.94M | 7.05M | Stockholders Equity |
| -2.56M | 8.39M | 3.10M | 8.84M | 3.44M | -150.96K |
| Cash Flow | Free Cash Flow | ||||
| -1.89M | -4.26M | -7.52M | -7.62M | -4.56M | -3.13M | Operating Cash Flow |
| -1.91M | -4.24M | -7.40M | -7.60M | -4.56M | -3.13M | Investing Cash Flow |
| 154.17K | -360.19K | -1.72M | -805.97K | -225.43K | -35.30K | Financing Cash Flow |
| 1.62M | 3.92M | 4.01M | 10.00M | 9.57M | 3.09M |
ABVC BioPharma, Inc. Technical Analysis
Positive
0.91
Price Trends
0.65
Positive
0.59
Positive
0.64
Positive
Market Momentum
0.11
Negative
88.22
Negative
92.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Positive. The current price of 0.91 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.65, and above the 200-day MA of 0.64, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 88.22 is Negative, neither overbought nor oversold. The STOCH value of 92.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVC.
ABVC BioPharma, Inc. Risk Analysis
ABVC BioPharma, Inc. disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma, Inc. reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ABVC BioPharma, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.04B | ― | -95.21% | ― | 9.03% | -25.00% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
42 Neutral | $9.64M | ― | -52.85% | ― | ― | 8.99% | |
38 Underperform | $10.54M | ― | -66.65% | ― | 157.63% | 40.52% | |
37 Underperform | $17.34M | ― | 249.03% | ― | 18.54% | 54.00% | |
34 Underperform | $13.46M | ― | -4693.38% | ― | ― | 56.38% | |
33 Underperform | $17.13M | ― | -90.91% | ― | -31.04% | 74.62% |
* Healthcare Sector Average
Performance Comparison
ABVC
ABVC BioPharma, Inc.
0.91
-0.37
-28.91%
PSTV
Plus Therapeutics
0.77
-1.15
-59.90%
OCUL
Ocular Therapeutix
7.00
-1.47
-17.36%
CLRB
Cellectar Biosciences
0.29
-3.43
-92.20%
CTXR
Citius Pharmaceuticals
1.03
-22.67
-95.65%
APRE
Aprea Therapeutics
1.80
-4.37
-70.83%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.